About NEUROFIT
NEUROFIT is a Healthcare company based in Illkirch-graffenstaden (France) founded in 1996, and was acquired by Domain Therapeutics in December 2019. A preclinical CRO specializing in nervous system disorder treatments. It operates on a Professional Services model. Its chief executive, as recorded, is Daniel Ejnes. NEUROFIT offers products and services including Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders. Its focus areas include Biotechnology and Preclinical Research. Its competitors include GenOway and TransCure bioServices; 2 of its 2 listed competitors have raised funding.
Company details
NEUROFIT is a preclinical Contract Research Organization focused on the evaluation of treatments for central and peripheral nervous system disorders. Services are provided through a comprehensive range of in vitro and in vivo models covering indications such as Alzheimers, Parkinsons, epilepsy, and neuropathic pain. Expertise is offered to guide model selection for drug screening and development. Customized experimental designs are adapted to client needs, supporting biopharmaceutical research with cost-effective evaluation methods across neurology, psychiatry, and inflammation sectors.
- Headquarters Illkirch-graffenstaden, France
- Stage Acquired
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website neurofit.com
- Social LinkedIn X
- Acquired by Domain Therapeutics (Dec 2019)
- Investors
- Acquired byDomain Therapeutics
(Dec 2019)
Products & Services of NEUROFIT
NEUROFIT offers a comprehensive portfolio of products and services, including Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders.
Services for evaluating treatments for CNS disorders offered.
Services for assessing treatments for PNS disorders provided.
Investors in NEUROFIT
NEUROFIT has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Domain Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
GPCR-targeted drug candidates for immuno-oncology and inflammation are developed. | 2008 | domaintherapeutics.com | Strasbourg, France |
Investor details for NEUROFIT
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NEUROFIT
1 people are tracked at NEUROFIT (1 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel Ejnes | CEO | Leadership |
Complete people profiles for NEUROFIT
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NEUROFIT
2 dated milestones of NEUROFIT across 23 years, from founding to its latest funding, stage changes and deals.
- Founded NEUROFIT is founded.
- Exit Acquired by Domain Therapeutics.
Competitors of NEUROFIT
NEUROFIT has 2 listed competitors in our database, 2 of them funded. They include GenOway and TransCure bioServices.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genoway.com | 1999 | Lyon, France | $11.55M | Provider of transgenic rodent models and customized cell lines for preclinical development | ||
| transcurebioservices.com | 2012 | Archamps, France | $3.58M | Humanized mouse models are developed for preclinical immune drug studies. |
Detailed competitors of NEUROFIT
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NEUROFIT
The website of NEUROFIT (neurofit.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 8.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurofit
Complete news archive for NEUROFIT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEUROFIT
NEUROFIT was founded in 1996.
NEUROFIT is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Daniel Ejnes is the CEO of NEUROFIT, as recorded in our data.
NEUROFIT is a preclinical Contract Research Organization focused on the evaluation of treatments for central and peripheral nervous system disorders. Services are provided through a comprehensive range of in vitro and in vivo models covering indications such as Alzheimers, Parkinsons, epilepsy, and neuropathic pain. Expertise is offered to guide model selection for drug screening and development. Customized experimental designs are adapted to client needs, supporting biopharmaceutical research with cost-effective evaluation methods across neurology, psychiatry, and inflammation sectors.
NEUROFIT's top competitors include GenOway and TransCure bioServices.
NEUROFIT offers Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders.
NEUROFIT has 1 investor. Key investors include Domain Therapeutics.
Yes. NEUROFIT was acquired by Domain Therapeutics in December 2019.

